Skip to content

Opinion

PBM reform: The end of the beginning

PBM reform: The end of the beginning

The recent release of an interim report by the Federal Trade Commission about what the agency characterizes as “prescription drug middlemen” represents a vindication of sorts for pharmacy advocates who have long contended that PBMs employ business practices that skew the market to their advantage.